Martin and colleagues’ latest study, published in June 2024 in JAMA Health Forum, finds that the Vot-ER project reaches a younger and more racially and ethnically diverse population, groups that are ...
Nivolumab plus AVD “should be a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin’s lymphoma,” according to researchers.
The FDA grants rare pediatric disease designation for serious or life-threatening diseases that affect fewer than 200,000 people in the United States when those people are primarily younger than 18 ...